Table 5.
Associations between pre-cART co-infections and percentage of CD4 naive T cells (CD4+ CD45RA+ CD62L+), by univariate and multivariate linear regression (n = 130), Mozambique*
| Factor | Crude difference† | 95% CI | P | Adjusted difference† | 95% CI | P |
|---|---|---|---|---|---|---|
| Pre-cART baseline factors* | ||||||
| CD4 cells | 2.33 | –2.96 to 7.62 | 0.386 | |||
| HIV RNA | 7.24 | –2.95 to 17.42 | 0.160 | |||
| WHO status | 2.97 | –2.25 to 8.20 | 0.262 | |||
| BMI | 2.15 | –3.02 to 7.33 | 0.412 | |||
| Age | −4.36 | –8.95 to 0.24 | 0.063 | −4.52 | –9.06 to –0.01 | 0.050 |
| Co-infections (+ vs. –) | ||||||
| HBV | 6.85 | 0.24–13.45 | 0.042 | 5.78 | –0.74 to 12.30 | 0.082 |
| HCV | −3.86 | –13.50 to 5.77 | 0.429 | |||
| KSHV | −4.96 | –9.49 to −0.43 | 0.032 | −6.84 | –11.33 to −2.35 | 0.003 |
| HTLV-I/II | −7.08 | –14.46 to 0.31 | 0.060 | −7.82 | –14.97 to −0.67 | 0.032 |
| Syphilis | −1.26 | –9.27 to 6.75 | 0.756 | |||
| Pf malaria | 6.47 | –3.80 to 16.74 | 0.215 | |||
| Tuberculosis | 1.10 | –3.98 to 6.18 | 0.670 | |||
Values are CD4 cell counts ≥ 200 vs. < 200 cells/mL; HIV RNA ≥ 5 log10 vs. < 5 log10 copies/mL; BMI ≤ 18.5 vs. > 18.5; WHO status III/IV vs. I/II. cART = combined antiretroviral therapy; HIV = human immunodeficiency virus; WHO = World Health Organization; BMI = body mass index; HBV = hepatitis B virus; HCV = hepatitis C vírus, KSHV = Kaposi sarcoma-associated herpesvirus; HTLV = Human T cell lymphotropic virus; Pf = Plasmodium falciparum.
The difference in percent activated CD8 T cells refers to the regression coefficient in linear regression analysis. Adjusted difference refers to the multivariable model including those variables with univariate P < 0.10 entered into a forward stepwise model. Final adjustment includes the variables appearing in the multivariate model (HIV RNA, HTLV-I/II, syphilis).